Literature DB >> 16575612

[Stem cell therapy. Biology of hematopoietic stem cells].

C Buske1, H Glimm, M Feuring-Buske.   

Abstract

In recent years much progress has been made in the understanding of the biology of hematopoietic stem cells (HSC) and their involvement in normal blood cell development. Using immunophenotyping it is possible, to enrich HSC, however, so far we are not able to positively select HSC. For the identification, characterization and quantification of HSC it is necessary to use functional assay systems, such as xenotransplantation models. HSC from bone marrow, peripheral blood and in some cases also cord blood have been used for years in transplantation settings especially in patients with leukemia. A better understanding of the mechanisms underlying stem cell regulation as well as stem cell self renewal would have clinical implications e. g. for clinical transplantation strategies. A number of hematological diseases such as chronic myeloid leukemia originates from a malignant transformed HSC. A better understanding of the biology of normal as well as malignant HSC is therefore crucial not only for a better understanding of the disease, but also for the development of strategies aiming at the discrimination of normal and malignant stem cell candidates and the development of therapies targeting the leukemic stem cell.

Entities:  

Mesh:

Year:  2006        PMID: 16575612     DOI: 10.1007/s00108-006-1602-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

1.  High marrow seeding efficiency of human lymphomyeloid repopulating cells in irradiated NOD/SCID mice.

Authors:  J D Cashman; C J Eaves
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice.

Authors:  H Glimm; W Eisterer; K Lee; J Cashman; T L Holyoake; F Nicolini; L D Shultz; C von Kalle; C J Eaves
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

3.  Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells.

Authors:  Christian Buske; Michaela Feuring-Buske; Carolina Abramovich; Karsten Spiekermann; Connie J Eaves; Laure Coulombel; Guy Sauvageau; Donna E Hogge; R Keith Humphries
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 4.  Ex vivo expansion of hematopoietic progenitor cells for clinical use.

Authors:  S Scheding; K Kratz-Albers; B Meister; W Brugger; L Kanz
Journal:  Semin Hematol       Date:  1998-07       Impact factor: 3.851

Review 5.  Normal and leukemic human stem cells assayed in SCID mice.

Authors:  J E Dick
Journal:  Semin Immunol       Date:  1996-08       Impact factor: 11.130

6.  Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro.

Authors:  H J Sutherland; C J Eaves; A C Eaves; W Dragowska; P M Lansdorp
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

7.  Enhanced in vivo regenerative potential of HOXB4-transduced hematopoietic stem cells with regulation of their pool size.

Authors:  U Thorsteinsdottir; G Sauvageau; R K Humphries
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

8.  A stem cell molecular signature.

Authors:  Natalia B Ivanova; John T Dimos; Christoph Schaniel; Jason A Hackney; Kateri A Moore; Ihor R Lemischka
Journal:  Science       Date:  2002-09-12       Impact factor: 47.728

9.  Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.

Authors:  Norbert Schmitz; Meral Beksac; Dirk Hasenclever; Andrea Bacigalupo; Tapani Ruutu; Arnon Nagler; Eliane Gluckman; Nigel Russell; Jane F Apperley; Norbert C Gorin; Jeff Szer; Ken Bradstock; Agnes Buzyn; Peter Clark; Keith Borkett; Alois Gratwohl
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

10.  Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells.

Authors:  J C van der Loo; H Hanenberg; R J Cooper; F Y Luo; E N Lazaridis; D A Williams
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

View more
  1 in total

1.  Safety and efficacy of ex vivo expanded CD34+ stem cells in murine and primate models.

Authors:  Yu Zhang; Bin Shen; Xin Guan; Meng Qin; Zhihua Ren; Yupo Ma; Wei Dai; Xinxin Ding; Yongping Jiang
Journal:  Stem Cell Res Ther       Date:  2019-06-13       Impact factor: 6.832

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.